Companies › Royal Biologics
1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Amnio-Maxx® Dual Layer Amnion Patch Cellular, acellular, matrix-like product (CAMP) derived from human amnion | – | Phase 4 | Diabetic Foot Ulcer (DFU) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07209475 | Amnio-Maxx® Dual Layer Amnion Patch | Phase 4 | Diabetic Foot Ulcer (DFU) | Metabolic and endocrine | Aug 2026 |
No annotated target.
–
PolarityTE HealthTech Wound Care Ascendis Pharma Bone Diseases BioXTek Blue Blood Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.